美国移植外科协会（ASTS）、美国移植协会（AST）、器官分享联合网络（UNOS）以及美国肾脏病协会（ASN）联合举办了针对肝肾联合移植（SLK）的的共识大会。25个最大的肝脏移植中心的负责人以及大会相关专业学术的讲者参加该会议。此次大会的目的在于提出SLK的指征、建立前瞻性的数据注册系统，而最重要的则是拟定出这些患者相关的标准。大会讨论了移植受者数据的科学注册以及单中心关于慢性肾脏疾病（CKD）以及与肝脏衰竭相关的急性肾脏损伤（AKI）作为SLK基础的单中心的数据。地方审查委员会（RRB）来决定SLK患者的名单，下列条件将获得自动通过：(i)终末期肾脏病，联合肝硬化及有症状的门脉高压，或者门脉楔压>/= 10 mm Hg；(ii)肝功能衰竭合并CKD，GFR</= 30 mL/min; (iii)AKI或者肝肾综合征肌酐水平>/= 2.0 mg/dL且透析超过8周；(iv)肝功能衰竭且CKD，活检证实超过30%的肾小球硬化或者纤维化。RRB可以用来评估其他项目的要求。

A consensus conference sponsored by the American Society of Transplant Surgeons (ASTS), American Society of Transplantation (AST), United Network for Organ Sharing (UNOS) and American Society of Nephrology (ASN) convened to examine simultaneous liver-kidney transplantation (SLK). Directors from the 25 largest liver transplant programs along with speakers with recognized expertise attended. The purposes of this conference were to propose indications for SLK, to establish a prospective data registry and, most importantly, to recommend standard listing criteria for these patients. Scientific registry of transplant recipients data, and single center data regarding chronic kidney disease (CKD) and acute kidney injury (AKI) in conjunction with liver failure as a basis for SLK was presented and discussed. The consensus was that Regional Review Boards (RRB) should determine listing for SLK, as with other MELD exceptions, with automatic approval for: (i) End-stage renal disease with cirrhosis and symptomatic portal hypertension or hepatic vein wedge pressure gradient >/= 10 mm Hg (ii) Liver failure and CKD with GFR </= 30 mL/min (iii) AKI or hepatorenal syndrome with creatinine >/= 2.0 mg/dL and dialysis >/= 8 weeks (iv) Liver failure and CKD and biopsy demonstrating > 30% glomerulosclerosis or 30% fibrosis. The RRB would evaluate all other requests to determine appropriateness.